142 related articles for article (PubMed ID: 38216819)
1. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; ; Blaes A
Breast Cancer Res Treat; 2024 Apr; 204(3):589-597. PubMed ID: 38216819
[TBL] [Abstract][Full Text] [Related]
2. Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.
Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; Blaes A
Res Sq; 2023 May; ():. PubMed ID: 37397981
[TBL] [Abstract][Full Text] [Related]
3. Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy.
Aguiar D; Ros L; Pérez D; Croissier L; Mori M; Hernández M; Vargas AM; Galván S; Antonilli C; Saura S
Breast Dis; 2022; 41(1):351-361. PubMed ID: 36031886
[TBL] [Abstract][Full Text] [Related]
4. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
5. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
6. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Warner ET; Ballman KV; Strand C; Boughey JC; Buzdar AU; Carey LA; Sikov WM; Partridge AH
Breast Cancer Res Treat; 2016 Aug; 159(1):109-18. PubMed ID: 27449492
[TBL] [Abstract][Full Text] [Related]
7. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
Litton JK; Gonzalez-Angulo AM; Warneke CL; Buzdar AU; Kau SW; Bondy M; Mahabir S; Hortobagyi GN; Brewster AM
J Clin Oncol; 2008 Sep; 26(25):4072-7. PubMed ID: 18757321
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
9. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
10. WITHDRAWN: Effect of obesity at the pathologic response to neoadjuvant chemotherapy among premenopausal Tunisian women with breast cancer.
Kacem M; Awatef M; Amel L; Jihen M; Slim BA
Obesity (Silver Spring); 2010 May; ():. PubMed ID: 20448536
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
12. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
13. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
14. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
15. Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Martel S; Lambertini M; Agbor-Tarh D; Ponde NF; Gombos A; Paterson V; Hilbers F; Korde L; Manukyants A; Dueck A; Maurer C; Piccart M; Moreno-Aspitia A; Desmedt C; Di Cosimo S; de Azambuja E
J Natl Compr Canc Netw; 2021 Jan; 19(2):181-189. PubMed ID: 33401235
[TBL] [Abstract][Full Text] [Related]
16. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer.
Chen S; Chen CM; Zhou Y; Zhou RJ; Yu KD; Shao ZM
PLoS One; 2012; 7(7):e41380. PubMed ID: 22848477
[TBL] [Abstract][Full Text] [Related]
17. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
Kogawa T; Fujii T; Fouad TM; Liu DD; Harano K; Masuda H; Iwase T; Barnett C; Park YS; Lim B; Tripathy D; Litton JK; Ueno NT
Breast Cancer Res Treat; 2018 Sep; 171(2):501-511. PubMed ID: 29915946
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Lammers SWM; Thurisch H; Vriens IJH; Meegdes M; Engelen SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Peters NAJB; Tol J; Heijns JB; van de Wouw AJ; Teeuwen NJA; Geurts SME; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jan; 203(2):339-349. PubMed ID: 37878148
[TBL] [Abstract][Full Text] [Related]
19. Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
Raman R; Mott SL; Schroeder MC; Phadke S; El Masri J; Thomas A
Clin Breast Cancer; 2016 Dec; 16(6):480-486. PubMed ID: 27431461
[TBL] [Abstract][Full Text] [Related]
20. Effect of Obesity on Neoadjuvant Systemic Therapy Outcomes in Patients with Early Breast Cancer: A Retrospective Institutional Study.
Rasmy A; Sorour Y
Asian Pac J Cancer Prev; 2020 Mar; 21(3):683-691. PubMed ID: 32212794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
